Immunosuppressive therapy and bone metabolism after kidney transplantation

被引:3
作者
Koller, H [1 ]
Mayer, G [1 ]
机构
[1] Univ Innsbruck, Innere Med Klin, Klin Abt Nephrol, A-6020 Innsbruck, Austria
关键词
renal osteopathy; immunosuppressive therapy; post-transplant osteoporosis; glucocorticoids; therapy of osteoporosis;
D O I
10.1046/j.1563-2571.2001.01019.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The success of transplant medicine due to improvements of immunosuppressive therapy has led to a significant increase of patient and organ survival. With the increasing number of transplantations, however, long term complications, often affecting the skeletal system, are becoming more frequent. Bone alterations often exist prior to transplantation in patients with chronic renal failure. There are two types of renal osteopathy, including "low-turnover bone disease", consisting of osteomalacia, and adynamic bone disease, and "high-turnover bone disease" due to the development of secondary hyperparathyroidism. Many patients show evidence of both disorders (mixed bone disease). During the first months after transplantation patients lose bone mass rapidly. One of the major factors responsible for the development of osteoporosis is thought to be the intensive immunosuppressive therapy during that period, steroids in particular seem to play an important role. To what extent other medications influence bone metabolism has not been established. Currently there are no studies about a standardized therapy and treatment relies mainly on experience with other forms of osteoporosis.
引用
收藏
页码:81 / 85
页数:5
相关论文
共 48 条
[1]   Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].
Adachi, JD ;
Bensen, WG ;
Brown, J ;
Hanley, D ;
Hodsman, A ;
Josse, R ;
Kendler, DL ;
Lentle, B ;
Olszynski, W ;
SteMarie, LG ;
Tenenhouse, A ;
Chines, AA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387
[2]   Prevention of osteoporosis in heart transplant recipients: A comparison of calcitriol with calcitonin and pamidronate [J].
Bianda, T ;
Linka, A ;
Junga, G ;
Brunner, H ;
Steinert, H ;
Kiowski, W ;
Schmid, C .
CALCIFIED TISSUE INTERNATIONAL, 2000, 67 (02) :116-121
[3]   Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management [J].
Block, GA ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (06) :1226-1237
[4]   HISTOMORPHOMETRIC PROFILE, PATHOPHYSIOLOGY AND REVERSIBILITY OF CORTICOSTEROID-INDUCED OSTEOPOROSIS [J].
BRESSOT, C ;
MEUNIER, PJ ;
CHAPUY, MC ;
LEJEUNE, E ;
EDOUARD, C ;
DARBY, AJ .
METABOLIC BONE DISEASE & RELATED RESEARCH, 1979, 1 (04) :303-311
[5]  
BRYER HP, 1995, J BONE MINER RES, V10, P132
[6]  
BUCKLEY LM, 1995, J RHEUMATOL, V22, P1055
[7]  
CANALIS E, 1992, J BONE MINER RES, V7, P1085
[8]   HORMONAL STATUS IN NORMAL, OSTEOPOROTIC AND CORTICOSTEROID-TREATED POST-MENOPAUSAL WOMEN [J].
CRILLY, R ;
CAWOOD, M ;
MARSHALL, DH ;
NORDIN, BEC .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1978, 71 (10) :733-736
[9]   Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation [J].
Cueto-Manzano, AM ;
Konel, S ;
Freemont, AJ ;
Adams, JE ;
Mawer, B ;
Gokal, R ;
Hutchison, AJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (02) :227-236
[10]  
CVETKOVIC M, 1994, TRANSPLANTATION, V57, P1237